Oncología médica
Specialty
Carlos
Camps Herrero
Publications by the researcher in collaboration with Carlos Camps Herrero (18)
2024
-
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC
Lung Cancer, Vol. 194
-
Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
British Journal of Cancer, Vol. 130, Núm. 3, pp. 417-424
2023
-
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer
New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513
2021
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
2019
-
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310
2018
-
Final results of RENO study: Randomized phase II of oral vinorelbine or etoposide with cisplatin & chemo-radiation in stage III NSCLC - SLCG 10/02
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii490
-
First analysis of patients (p) with stage IV non-small cell lung cancer (NSCLC) of the thoracic tumor registry (RTT) of the Spanish Lung Cancer Group (SLCG)
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii535-viii536
-
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii38
2014
-
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: The BRCA1-RAP80 Expression Customization (BREC) studies
Annals of Oncology, Vol. 25, Núm. 11, pp. 2147-2155
2010
-
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients
Lung Cancer, Vol. 68, Núm. 3, pp. 491-497
2009
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
2007
-
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer
Journal of Clinical Oncology, Vol. 25, Núm. 19, pp. 2747-2754
2006
-
The place of targeted therapies in the management of non-small cell bronchial carcinoma: Molecular markers as predictors of tumor response and survival in lung cancer
Revue des Maladies Respiratoires, Vol. 23, Núm. 5 C3
2004
-
Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: Randomized phase II trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study
Annals of Oncology, Vol. 15, Núm. 1, pp. 79-87
-
Single nucleotide polymorphisms and outcome in docetaxel - Cisplatin-treated advanced non-small-cell lung cancer
Annals of Oncology, Vol. 15, Núm. 8, pp. 1194-1203
2003
-
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial
Journal of Clinical Oncology, Vol. 21, Núm. 17, pp. 3207-3213
-
Influence of genetic markers on survival in non-small cell lung cancer
Drugs of Today, Vol. 39, Núm. 10, pp. 775-786